Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate

Abstract

Elevated serum phosphate levels as a consequence of chronic kidney disease (CKD) contribute to the increased cardiovascular risk observed in dialysis patients. Protein restriction and dialysis fail to adequately prevent hyperphosphatemia, and in general treatment with oral phosphate binding agents is necessary in patients with advanced CKD. Phosphate plays… (More)

3 Figures and Tables

Topics

  • Presentations referencing similar topics